BETHLEHEM, Pa., April 13 /PRNewswire/ -- Particle Sciences Inc. (PSI), a leading pharmaceutical CRO, is adding to its portfolio of drug delivery technologies through the acquisition of a versatile PEG-based technology. The technology covers a series of PEG-grafted cationic polymers that have a wide variety of applications in the pharmaceutical arena.
“Particle Sciences has been working with this technology for some time now and we are very happy with the performance and in vivo tolerability results obtained thus far in several different systems. To bolster the acquired technology, we have filed additional intellectual property to both broaden and extend its patent coverage,” added Andrew Loxley, Particle Sciences’ Director of New Technologies.
Particle Sciences Inc.
